Relationship between plasma matrix metalloproteinase-9 and hemorrhagic transformation in ischemic stroke: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 6, Issue 5, 2006, Pages 361-369

  Cao, Xin Hui ^a   Liu, Ming ^a   Wu, Bo ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Hemorrhagic transformation; Matrix metalloproteinase 9; Systematic review; Thrombolytic therapy

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CONTROLLED STUDY; DATA ANALYSIS; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; REVIEW;

EID: 33744899877     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Hacke W, Kaste M, Fieschi C, et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for actue hemispheric stroke. JAMA, 1995; 274(13): 1017-1025.
2. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for actue ischemic stroke. N Engl J Med, 1995; 333(24): 1581-1587.
3. The Multicenter Acute Stroke Trial Europe Study Group. Thrombolytic therapy with Streptokinasein acute ischemic stroke. N Engl J Med, 1996; 335(3): 145-150.
4. Rosenberg GA, Navratil M, Barone F, et al. Proteolytic casecade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Metab, 1995; 16(3): 360-366.
5. Gasche Y, Fujimura M, Morita- Fujimura Y, et al. Early appearance of activated matrix metalloprotienase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfuntion. J Cereb Blood Metab, 1999; 19(9): 1020-1028.
6. Wang JL. Clinical epidemiology-design, weigh, and evaluation of clinical research. Edi 2. Shanghai: Shanghai Publishing Company of Science and Technology; 2001. 297.
7. Liu JP. Method to systematic reviews of non-RCT. Chinese Journal of Evidence-Based Medicine, 2001; 1(4): 239-243.
8. Liu JP. Method to systematic reviews of non-RCT. Chinese-Journal of Evidence-Based Medicine, 2002; 2(1): 44-48.
9. Castellanos M, Leila R, Serena J, et al. Plasma Cellular-Fibronectin Concentration Predicts Hemorrhagic Transformation After Thrombolytic Therapy in Acute Ischemic Stroke. Stroke, 2004; 35(7): 1671-1676.
10. Montaner J, Molina CA, Monasterio J, et al. Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke. Circulation, 2003; 107(4): 598-603.
11. Montaner J, Fernández-Cadenas I, Molina CA, et al. Safety Profile of Tissue Plasminogen Activator Treatment Among Stroke Patients Carrying a Common Polymorphism (C-1562T) in the Promoter Region of the Matrix Metalloproteinase-9 Gene. Stroke, 2003; 34(12): 2851-2855.
12. Montaner J, Alvarez-Sabin J, Molina CA, et al. Matrix Metalloproteinase Expression Is Related to Hemorrhagic Transformation After Cardioembolic Stroke. Stroke, 2001; 32(12): 2762-2767.
13. Castellanos M, Leira R, Serena J, et al. Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke. Stroke, 2003; 34(1): 40-46.
14. Tan S, Liu M. Study on relationship between plasma matrix metalloproteinase-9 level and hemorrhagic transformation in acute ischemic stroke. 2005 doctoral paper of Sichan university.
15. Kake W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous Alteplase in acute ischemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet, 1998; 352: 1245-1251.